Novago Therapeutics AG

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Based in Zurich, Switzerland, NovaGo Therapeutics is a development stage biotech company focused on human antibody therapeutics targeting blood vessel growth, nerve growth, and regeneration.
NovaGo is planning to initiate clinical development of our anti-Nogo-A monoclonal antibody, NG004, in diabetic retinopathy in Q1 2022.
We are currently looking for investors interested in helping NovaGo deliver on our mission of changing the treatment paradigm for patients with diabetic retinopathy.
Company Type:
Privately Funded Company
Company HQ State:
Not Provided
Company HQ Country:
Switzerland
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
NG004
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
photo
CEO
NovaGo Therapeutics AG